| Aug 23 |
Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report
|
| Aug 19 |
Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
|
| Aug 19 |
More promise for psilocybin in depression but safety remains a concern
|
| Aug 15 |
Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD
|
| Aug 15 |
Psychedelic Stocks: Focus On Their Cash
|
| Aug 12 |
FDA Rejection of MDMA Therapy Isn’t End of Psychedelic-Drug Candidates
|
| Aug 12 |
Medical journal retracts three articles related to MDMA for PTSD
|
| Aug 9 |
Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA
|
| Aug 6 |
COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference
|
| Aug 4 |
COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript
|
